Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give Scholar Rock a “Moderate Buy” consensus: Among 17 analysts, 10 rated the stock a buy and four a strong buy, while two rated it a sell and one a hold. The average 12-month price target is $67.67.
• Recent analyst actions were generally positive, with Piper Sandler, Citigroup and HC Wainwright raising price targets to $75, $74 and $70, respectively; Barclays downgraded the stock to “cautious.”
• Institutional investors own 91.08% of the company. SRRK opened at $42.20, below its $61.76 52-week high, while Scholar Rock reported quarterly EPS of negative $0.84, in line with analyst expectations.

Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seventeen research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and four have given a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $67.67.

Several analysts recently issued reports on SRRK shares. Piper Sandler raised their price target on Scholar Rock from $60.00 to $75.00 and gave the stock an "overweight" rating in a report on Tuesday, September 15th. Barclays lowered Scholar Rock from an "overweight" rating to a "cautious" rating in a report on Tuesday, September 15th. Citigroup boosted their target price on Scholar Rock from $60.00 to $74.00 and gave the stock a "buy" rating in a report on Monday, September 14th. HC Wainwright boosted their price target on shares of Scholar Rock from $65.00 to $70.00 and gave the stock a "buy" rating in a research report on Tuesday, September 15th. Finally, Evercore reaffirmed an "outperform" rating and issued a $72.00 price target on shares of Scholar Rock in a report on Tuesday, September 15th.

Institutional Trading of Scholar Rock

A number of hedge funds have recently modified their holdings of the business. GAMMA Investing LLC grew its position in Scholar Rock by 20.8% in the second quarter. GAMMA Investing LLC now owns 1,406 shares of the company's stock worth $77,000 after acquiring an additional 242 shares in the last quarter. Values First Advisors Inc. increased its stake in shares of Scholar Rock by 1.5% in the first quarter. Values First Advisors Inc. now owns 18,850 shares of the company's stock worth $927,000 after purchasing an additional 286 shares during the period. Syon Capital LLC lifted its holdings in shares of Scholar Rock by 6.4% during the second quarter. Syon Capital LLC now owns 9,782 shares of the company's stock worth $538,000 after buying an additional 588 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Scholar Rock by 92.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,270 shares of the company's stock valued at $62,000 after purchasing an additional 610 shares during the last quarter. Finally, Allworth Financial LP bought a new stake in shares of Scholar Rock in the second quarter valued at about $35,000. Hedge funds and other institutional investors own 91.08% of the company's stock.

Scholar Rock Price Performance

Shares of NASDAQ:SRRK opened at $42.20 on Friday. The company has a quick ratio of 7.02, a current ratio of 7.02 and a debt-to-equity ratio of 0.77. Scholar Rock has a fifty-two week low of $27.07 and a fifty-two week high of $61.76. The firm has a 50-day simple moving average of $51.73 and a 200 day simple moving average of $50.00. The company has a market cap of $5.14 billion, a PE ratio of -12.23 and a beta of 0.61.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.84). During the same quarter in the prior year, the firm posted ($0.98) earnings per share. On average, sell-side analysts anticipate that Scholar Rock will post -3.23 EPS for the current year.

Scholar Rock Company Profile

Scholar Rock Holding Corporation NASDAQ: SRRK is a clinical-stage biopharmaceutical company focused on developing medicines that selectively target the activation of growth factors. The company's approach is designed to modulate biologic pathways in specific tissues while potentially limiting effects elsewhere in the body.

Scholar Rock's lead product candidate is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin, a protein that negatively regulates muscle growth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.